To demonstrate the role of NRF2 in RTK signaling and thus in determining responses to targeted therapies, we used HER2 overexpressing (SKOV3) and low expressing (PEO1) ovarian cancer cell lines [57] grown in HER receptor ligand Heregulin and employed pharmacological and genetic activation or inhibition of both NRF2-AR and HER2/HER3 signaling pathways. The gene discussed is ERBB3; the disease is ovarian cancer.